1. Home
  2. WERN vs NVAX Comparison

WERN vs NVAX Comparison

Compare WERN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Werner Enterprises Inc.

WERN

Werner Enterprises Inc.

HOLD

Current Price

$28.88

Market Cap

2.0B

Sector

Industrials

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.77

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WERN
NVAX
Founded
1956
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
WERN
NVAX
Price
$28.88
$9.77
Analyst Decision
Hold
Buy
Analyst Count
16
9
Target Price
★ $41.13
$14.22
AVG Volume (30 Days)
709.5K
★ 8.1M
Earning Date
10-27-2026
11-05-2026
Dividend Yield
★ 1.92%
N/A
EPS Growth
N/A
★ 309.76
EPS
★ 0.03
N/A
Revenue
★ $2,974,396,000.00
$1,123,479,000.00
Revenue This Year
$22.79
N/A
Revenue Next Year
$8.00
N/A
P/E Ratio
$974.83
★ N/A
Revenue Growth
N/A
★ 64.69
52 Week Low
$23.06
$6.20
52 Week High
$47.49
$13.39

Technical Indicators

Market Signals
Indicator
WERN
NVAX
Relative Strength Index (RSI) 26.11 40.84
Support Level $26.62 $7.93
Resistance Level $35.45 $10.26
Average True Range (ATR) 1.08 1.10
MACD -0.26 -0.32
Stochastic Oscillator 16.17 5.28

Price Performance

Historical Comparison
WERN
NVAX

About WERN Werner Enterprises Inc.

Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: